Stock Analysis
Mabion Full Year 2023 Earnings: EPS: zł2.55 (vs zł1.44 in FY 2022)
Mabion (WSE:MAB) Full Year 2023 Results
Key Financial Results
- Revenue: zł151.7m (down 7.5% from FY 2022).
- Net income: zł41.3m (up 78% from FY 2022).
- Profit margin: 27% (up from 14% in FY 2022). The increase in margin was driven by lower expenses.
- EPS: zł2.55 (up from zł1.44 in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Mabion Earnings Insights
Looking ahead, revenue is expected to decline by 1.1% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Europe are expected to grow by 18%.
Performance of the market in Poland.
The company's shares are up 3.1% from a week ago.
Risk Analysis
We don't want to rain on the parade too much, but we did also find 3 warning signs for Mabion (2 are potentially serious!) that you need to be mindful of.
Valuation is complex, but we're helping make it simple.
Find out whether Mabion is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About WSE:MAB
Mabion
Mabion S.A., a biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland.
Solid track record with adequate balance sheet.